

Nahdi Medical Company

Sector : Pharma Retail

HOLD

20 May 2026

- Nahdi reported record quarterly revenue in 1Q26 growing by 6.1% YoY and much in line with our estimates. Both front shop and pharma grew by mid-single digits. Revenue growth was backed by 1,223 outlets and 14 clinics. Healthcare and UAE expansion contributed 6% to the topline, while Wasfaty added to the volumes.
- Gross margin slipped 75bps YoY, higher opex led to decline in operating profit by -4% YoY during the quarter. Net profit also declined by 7.8% coming closer to our estimate.
- We retain 2026e revenue but reduce the profit estimate slightly considering the lower margins during the quarter. The target price stands reduced at SAR 105.15 per share and we recommend to HOLD.

Revenue increased 6.1% YoY in 1Q26, in line with our expectations, supported by a 3.0% YoY increase in front-shop sales and 5.3% YoY growth in the pharma segment. This marks the highest quarterly revenue reported by the company in its history. Growth was achieved despite macroeconomic headwinds and softer consumer spending trends. The healthcare and UAE businesses grew by 34.8% and 31.8% YoY, respectively. Although these segments were launched only a few years ago, they have scaled up well and currently contribute 6% of topline revenue, compared with 3% in 2024 and 5% in 2025. These businesses have also complemented pharmacy volumes effectively. Online sales continue to gain traction and currently account for 30.7% of topline revenue. The recently launched Wasfaty program recorded a 22% QoQ increase in volumes, further supporting revenue growth. Nahdi's push toward private-label sales has also shown positive momentum, with contribution rising to 18.4% compared with 17% in 2025. We believe this should help support margins going forward.


Gross margin declined by 75bps during the quarter due to cost escalation, resulting in a moderation in gross profit growth to 3.9% YoY. Operating expenses increased 7% YoY, driven by the addition of new outlets and clinics. The contraction in operating margins led to a 4% YoY decline in operating profit, while EBITDA remained broadly flat. Lower finance income and a higher tax provision also weighed on the bottom line. Overall, net profit came in at SAR 236mn, down 7.8% YoY but broadly in line with our estimates.

Valuation: Nahdi has continued to grow its topline despite several macroeconomic headwinds, reflecting the effectiveness of its strategy to diversify its product and service offerings. The company remains a key player in the healthcare value chain and maintains a leadership position within the segment. However, the increasing penetration of online shopping, coupled with softer demand conditions, continues to pressure margins and growth. While the company has maintained its guidance, we believe margin pressure may persist, potentially weighing on earnings growth. We therefore maintain our 2026e revenue forecast while slightly lowering our profit estimates. The stock is trading near the lower end of its historical valuation range and we see limited downside from here. However, based on the revised forecast we reduce our target price to SAR 105.15 per share. Accordingly, we maintain our HOLD rating on the stock.

Target price (SAR) **105.15**

Current price (SAR) **98.50**

Return **6.80%**



Exchange Saudi Arabia
Index weight (%) 0.3%

(mn)	SAR	USD
Market Cap	12,805	3,457
Enterprise value	13,834	3,735

Major share holders

Alnahdi Holding Co L	38.1%
Saudi Economic & Dev	25.0%
Al Misbahi Ibrahim A	6.9%
Others	30.0%

Valuation Summary (TTM)

PER TTM (x)	14.5
P/Book (x)	5.2
EV/EBITDA (x)	7.8
Dividend Yield (%)	4.8
Free Float (%)	30%
Shares O/S (mn)	130
YTD Return (%)	4%
Beta	0.7

Key ratios	2023	2024	2025
EPS (SAR)	6.87	6.31	6.39
BVPS (SAR)	18.94	19.89	21.10
DPS (SAR)	5.50	5.50	5.60
Payout ratio (%)	80%	87%	88%

Price performance (%)	1M	3M	12M
Nahdi Medical Co	-8%	2%	-18%
Tadawul All Share Index	-3%	0%	-4%

52 week	High	Low	CTL*
Price (SAR)	132.10	91.00	8.2

* CTL is % change in CMP to 52w k low



Income Statement (In SAR mn)	2022	2023	2024	2025	2026e	2027e	2028e	2029e
Revenue	8,616	8,714	9,446	10,213	10,637	11,534	12,529	13,844
Direct Costs	-5,095	-5,191	-5,914	-6,408	-6,839	-7,324	-7,956	-8,791
Gross profit	3,521	3,522	3,533	3,806	3,798	4,210	4,573	5,053
Selling and distribution expenses	-2,240	-2,249	-2,342	-2,521	-2,520	-2,826	-3,069	-3,392
General and administrative expenses	-331	-337	-347	-378	-371	-415	-451	-498
Other operating income (Net)	52	24	29	20	22	58	63	69
Operating profit	1,002	961	873	927	929	1,027	1,115	1,232
EBITDA	1,598	1,579	1,577	1,721	1,733	1,919	2,085	2,292
Finance income	12	65	59	61	194	60	60	60
Finance costs	-79	-83	-116	-142	-246	-124	-136	-149
Other costs	3	2	18	0	0	0	0	0
Profit before tax	937	944	835	846	878	963	1,039	1,144
Income tax and Zakat	-50	-52	-14	-15	-35	-48	-52	-57
Net profit	887	893	821	831	842	915	987	1,087

Balance Sheet (in SAR mn)	2022	2023	2024	2025	2026e	2027e	2028e	2029e
Property, plant and equipment	914	1,040	1,113	1,203	1,330	1,421	1,501	1,579
Investment property	254	254	256	256	256	256	256	256
Intangible assets	47	51	69	68	67	67	67	67
Right of use assets	1,167	1,267	1,607	1,825	1,884	1,968	2,076	2,214
Non-current assets	2,382	2,613	3,062	3,392	3,575	3,751	3,939	4,155
Inventories	1,183	1,409	1,711	2,278	2,431	2,604	2,828	3,125
Trade receivables	130	173	136	261	272	295	321	354
Prepayment and other current assets	174	267	308	204	212	230	250	276
Cash and cash equivalents	1,076	910	957	554	1,115	1,422	1,714	2,006
Current assets	2,563	2,759	3,111	3,299	4,133	4,653	5,215	5,864
ASSETS	4,945	5,371	6,173	6,691	7,708	8,404	9,153	10,019
Share capital	1,300	1,300	1,300	1,300	1,300	1,300	1,300	1,300
Statutory reserve	280	369	369	0	-	-	-	-
Retained earnings	664	794	917	1,443	1,612	1,795	1,992	2,210
EQUITY	2,244	2,463	2,586	2,744	2,912	3,095	3,292	3,510
Employee defined benefits	381	392	420	421	479	513	557	615
Lease liabilities	792	871	1,146	1,363	1,608	1,851	2,081	2,324
Accruals and other non-current liabilities	20	15	15	15	-	-	-	-
Non-current liabilities	1,193	1,277	1,581	1,800	2,087	2,363	2,638	2,940
Lease liabilities	375	304	383	420	536	617	694	775
Provision for zakat/ Zakat payable	107	113	77	51	44	48	52	57
Trade payables	637	894	1,249	1,419	1,514	1,622	1,761	1,946
Accruals and other non-current liabilities	389	320	297	258	616	659	716	791
Current liabilities	1,508	1,631	2,006	2,148	2,710	2,946	3,223	3,569
LIABILITIES	2,701	2,909	3,587	3,947	4,796	5,309	5,861	6,509
EQUITY AND LIABILITIES	4,945	5,371	6,173	6,691	7,708	8,404	9,153	10,019

Cash Flow (In SAR mn)	2022	2023	2024	2025	2026e	2027e	2028e	2029e
Cash from operations	1,670	1,369	1,491	1,134	1,999	1,786	1,928	2,099
Investing cash flow	-277	-384	-328	-354	-141	3	17	34
Financing cash flow	-717	-1,151	-1,117	-1,182	-1,298	-1,482	-1,654	-1,840
Change in cash	676	-166	46	-403	562	306	293	292
Beginning cash	400	1,076	910	956	554	1,115	1,422	1,714
Ending cash	1,076	910	956	554	1,115	1,422	1,714	2,006



Ratio Analysis	2022	2023	2024	2025	2026e	2027e	2028e	2029e
Per Share								
EPS (SAR)	6.82	6.87	6.31	6.39	6.48	7.04	7.59	8.36
BVPS (SAR)	17.26	18.94	19.89	21.10	22.40	23.81	25.33	27.00
DPS (SAR)	2.31	5.50	5.50	5.60	5.18	5.63	6.08	6.69
FCF per share (SAR)	10.72	7.57	8.95	6.00	14.30	13.77	14.96	16.40
Valuation								
Market Cap (SAR mn)	21,736	17,810	16,042	12,350	12,805	12,805	12,805	12,805
EV (SAR mn)	21,827	18,075	16,615	13,579	13,834	13,850	13,866	13,898
EBITDA	1,598	1,579	1,577	1,721	1,733	1,919	2,085	2,292
P/E (x)	24.5	20.0	19.5	14.9	15.2	14.0	13.0	11.8
EV/EBITDA (x)	13.7	11.4	10.5	7.9	8.0	7.2	6.7	6.1
Price/Book (x)	9.7	7.2	6.2	4.5	4.4	4.1	3.9	3.6
Dividend Yield (%)	1.4%	4.0%	4.5%	5.9%	5.3%	5.7%	6.2%	6.8%
Price to sales (x)	2.5	2.0	1.7	1.2	1.2	1.1	1.0	0.9
EV to sales (x)	2.5	2.1	1.8	1.3	1.3	1.2	1.1	1.0
Liquidity								
Cash Ratio (x)	0.71	0.56	0.48	0.26	0.41	0.48	0.53	0.56
Current Ratio (x)	1.70	1.69	1.55	1.54	1.53	1.58	1.62	1.64
Quick Ratio (x)	0.80	0.66	0.54	0.38	0.55	0.62	0.66	0.69
Returns Ratio								
ROA (%)	17.9%	16.6%	13.3%	12.4%	10.9%	10.9%	10.8%	10.8%
ROE (%)	39.5%	36.2%	31.7%	30.3%	28.9%	29.6%	30.0%	31.0%
ROCE (%)	25.8%	23.9%	19.7%	18.3%	16.9%	16.8%	16.6%	16.8%
Cash Cycle								
Inventory turnover (x)	4.3	3.7	3.5	2.8	2.8	2.8	2.8	2.8
Accounts Payable turnover (x)	8.0	5.8	4.7	4.5	4.5	4.5	4.5	4.5
Receivables turnover (x)	66.3	50.4	69.7	39.1	39.1	39.1	39.1	39.1
Inventory days	85	99	106	130	130	130	130	130
Payable Days	46	63	77	81	81	81	81	81
Receivables days	6	7	5	9	9	9	9	9
Cash Cycle	45	43	34	58	58	58	58	58
Profitability Ratio								
Net Margins (%)	10.3%	10.2%	8.7%	8.1%	7.9%	7.9%	7.9%	7.8%
EBITDA Margins (%)	18.5%	18.1%	16.7%	16.9%	16.3%	16.6%	16.6%	16.6%
PBT Margins (%)	10.9%	10.8%	8.8%	8.3%	8.3%	8.3%	8.3%	8.3%
EBIT Margins (%)	11.6%	11.0%	9.2%	9.1%	8.7%	8.9%	8.9%	8.9%
Effective Tax Rate (%)	5.3%	5.5%	1.7%	1.8%	4.0%	5.0%	5.0%	5.0%
Leverage								
Total Debt (SAR mn)	1,167	1,175	1,530	1,783	2,144	2,468	2,775	3,099
Net Debt (SAR mn)	91	265	573	1,229	1,029	1,045	1,061	1,093
Debt/Equity (x)	0.5	0.5	0.6	0.7	0.7	0.8	0.8	0.9
Net Debt/Equity (x)	0.0	0.1	0.2	0.4	0.4	0.3	0.3	0.3




Key contacts

Research Team

		Contact Address
Joice Mathew	Manna Thomas ACCA	P. O Box: 2566; P C 112
Sr. Manager - Research	Research Associate	Sultanate of Oman
E-Mail: joice@usoman.com	Email: manna.t@usoman.com	Tel: +968 2476 3300
Tel: +968 2476 3311	Tel: +968 2476 3347	

Rating Criteria and Definitions

Rating



Rating Definitions

Strong Buy	This recommendation is used for stocks whose current market price offers a deep discount to our 12-Month target price and has an upside potential in excess of 20%
Buy	This recommendation is used for stocks whose current market price offers a discount to our 12-Month target price and has an upside potential between 10% to 20%
Hold	This recommendation is used for stocks whose current market price offers a discount to our 12-Month target price and has an upside potential between 0% to 10%
Neutral	This recommendation is used for stocks whose current market price offers a premium to our 12-Month target price and has a downside side potential between 0% to -10%
Sell	This recommendation is used for stocks whose current market price offers a premium to our 12-Month target price and has a downside side potential between -10% to -20%
Strong Sell	This recommendation is used for stocks whose current market price offers a premium to our 12-Month target price and has a downside side potential in excess of 20%
Not rated	This recommendation used for stocks which does not form part of Coverage Universe

Disclaimer

This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person. Persons into whose possession this document may come are required to observe these restrictions. Opinion expressed is our current opinion as of the date appearing on this material only. We do not undertake to advise you as to any change of our views expressed in this document. While we endeavor to update on a reasonable basis the information discussed in this material, United Securities, its subsidiaries and associated companies, their directors and employees are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true and are for general guidance only. While every effort is made to ensure the accuracy and completeness of information contained, the company takes no guarantee and assumes no liability for any errors or omissions of the information. No one can use the information as the basis for any claim, demand or cause of action.

Recipients of this material should rely on their own investigations and take their own professional advice. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. United Securities LLC, and affiliates, including the analyst who has issued this report, may, on the date of this report, and from time to time, have long or short positions in, and buy or sell the securities of the companies mentioned herein or engage in any other transaction involving such securities and earn brokerage or compensation or act as advisor or have other potential conflict of interest with respect to company/ies mentioned herein or inconsistent with any recommendation and related information and opinions. United Securities LLC and affiliates may seek to provide or have engaged in providing corporate finance, investment banking or other advisory services in a merger or specific transaction to the companies referred to in this report, as on the date of this report or in the past.